There is no need to stress the importance of the Coronavirus disease (COVID-19) for public health, economic consequences, and the well-being of individuals. Yet, there is a need for more knowledge about objective information and reliable predictions of how the pandemic will likely evolve in the months to come. How large is the risk of any individual to become sick on a particular day or within a week? How does this risk change over time? How large is the expected number of individuals ever infected, and how large is the number of individuals infected at any point in time (prevalence)? The latter question is the main concern of the public, politicians and health practitioners to ensure sufficient provisions of health services. Finally, what are the effects of policy interventions that are already in place and that are being discussed?
This paper starts by describing what we know quantitatively about the spread of the Corona epidemic in the Chinese province of Hubei and in South Korea. This offers insights from two episodes of epidemics that seem to be coming to an end and that help in making predictions for other countries. We then compare the time-series evidence from Hubei and South Korea with cross-sectional information in European countries.
Section 3 develops an epidemiological Markov model. We start from individuals that can be in four states: healthy (the initial state, state 1), infected and sick (state 2), infected and recovered or infected and never having displayed symptoms (state 3), and deceased (state 4). Individuals move between these states with endogenous transition rates that depend on population characteristics. This model allows us to make predictions, inter alia, about all the quantities of interest that appeared in the initial questions.
We apply this model to Germany. We choose parameter values such that the time series of the number of sick (and reported) individuals in Germany since 24 February is matched by our model. Our data source is the Robert Koch Institute (RKI, 2020). In order to predict the future evolution, we build on various evidence from epidemiology such as individual sickness probability and long-run infection rates of the whole population. We emphasize the scarce medical and statistical knowledge on these parameters. Any predictions therefore must be subject to large variations. We accordingly undertake robustness checks with respect to our central parameters.
Given our calibration for the epidemic without public intervention, we predict prevalence, i. e. the number of sick individuals at each point in time. We compute when the peak will be reached and whether medical services are in sufficient supply. We also undertake counterfactual analysis to understand when drastic policy measures (e. g. shutting down educational institutions or canceling big public events) are most effective.
We have four general findings: First, current epidemiological thinking implies that the long-run effects of the epidemic only depend on the aggregate long-run infection rate and the individual risk to become sick after an infection. Any measures by individuals and the public therefore only influence the dynamics of the spread of SARS-CoV-2 (severe acute respiratory syndrome due to corona virus 2).1 Second, predictions about the duration and level of the epidemic must strongly distinguish between the officially reported numbers (Robert Koch Institut, RKI) and actual numbers of sick individuals. Third, given the current (scarce) medical knowledge about long-run infection rates and individual risks to fall sick for CoV-2, any prediction on the length (duration in months) and strength (e. g. maximum numbers of sick individuals on a given day) of the outbreak is subject to uncertainty. Our predictions therefore offer robustness analyses that provide ranges on how long the epidemic will last and how strong it will be. Fourth, comparing one public intervention to another public intervention shows that an intervention can lead to either more or less severe outcomes of the epidemic. If an intervention takes place too early, peak prevalence can actually be higher than with an intervention that starts later. Depending on the outcome measure, an intervention can also be worse than no intervention. Interventions should therefore be contingent on current infection rates in regions or countries.
Concerning predictions about COVID-19 in Germany, we find that the long-run number of sick individuals (that are reported to the RKI), once the epidemic is over, will lie between 500,000 and 5 million individuals. While this seems to be an absurdly large range for a precise projection, this reflects the uncertainty about the long-run infection rate in Germany. If we assume that Germany will follow the good scenario of Hubei (and our projections are even a bit more conservative given discussions about data quality), Germany will end up with 500,000 sick individuals over the entire epidemic. If by contrast we believe (as many argue) that once the epidemic is over, 70 % of the population will have been infected (and thereby immune), Germany will end up with 5 million cases.
Defining the end date of the epidemic as the first day with less than 100 incidences, i. e. newly reported sick individuals per day, we find a large variation of outcomes depending on the effectiveness of governmental pleas and regulations to reduce social contacts. An epidemic that is not influenced by public health measures would end in mid-June 2020. With public health measures lasting for few weeks, the end is delayed by around one to two months. The delay is advantageous because it reduces the peak number of individuals that are simultaneously sick. When we believe in long-run infection rates of 70 %, peak prevalence is equally high for all scenarios we went through and well above 1 million. When we can hope for the Hubei-scenario, the maximum number of sick individuals will “only” be around 200,000. Whatever value of the range of long-run infection rates we want to assume, the epidemic will last at least until June, with extensive and potentially future public health measures, it will last until July. In the longest case, it will last until end of August.2
There is an exploding literature on these issues, especially in medical science. The classic large-scale spatial model is described in Balcan et al. (2010). It is applied in Chinazzi et al. (2020) to study the effect of a travel ban on China and the world. Akbarpour and Jackson (2018) study a general model of infection, but cannot provide applications to the current epidemic. The widely discussed study by Ferguson et al. (2020) focuses on the US and the UK.3 An insightful study on the usefulness of isolation strategies for COVID-19 based on a stochastic transition model similar to ours is by Hellewell et al. (2020). Wilder-Smith et al. (2020) discuss the similarities and differences between the SARS 2003 (severe acute respiratory syndrome) epidemic and COVID-19. One big issue is the large number of “quiet infections” in COVID-19 as opposed to SARS 2003, an aspect we will capture in our model below.
The analyses which come closest to ours are two notes by the Deutsche Gesellschaft für Epidemiologie (DGfE, 2020) and by an der Heiden and Buchholz (2020). DGfE (2020) offer predictions based on a model similar to ours (so called SEIR models, see e. g. Anderson et al., 1992). We present our model in detail, including the stochastic foundation, and discuss the implications of the modelling assumptions.4 Modelling assumptions turn out to be crucial for evaluating public policy measures. We also implement in detail the effects of policy measures and discuss the trade-offs with respect to length and strength of the evolution of the epidemic. The match of the model with the data also differs. While DGfE (2020) seem to use summary statistics for their calibration, we determine the parameters of our model by fitting our model predictions to the data. This offers the advantage that we can update our predictions whenever new data is available.
The study by an der Heiden and Buchholz (2020) is, to the best of our knowledge, the most elaborate study at this point for Germany. We share their belief that mathematical models help in studying the effects of policy measures. Many parameters of their analysis are derived from knowledge on the epidemic in China and especially the city Shenzen. We calibrate many of our central parameters such that the model fits the observations in Germany. We also share with them the approach of using SEIR models. Our paper emphasises the implications of the fundamental model assumptions for the prediction. We find below that the evaluation of policy measures crucially depends on these model assumptions. We make these model assumptions explicit in our paper and discuss the effects of variations in these assumptions.
Why should economists work on an epidemic? The economic costs of COVID-19 are huge and seem to be larger than those of the financial crisis starting in 2007.5 This paper provides a model that allows us to understand the spread of the disease. We employ a model in the tradition of search and matching models originating from Diamond (1982), Mortensen (1982) and Pissarides (1985). The basic structure of these models (continuous time Markov chains) is identical to epidemiological models (which is clear from overviews such as Hethcote, 2000).6 Compared to standard search and matching models, we allow for four states, however. We extend the typical matching framework from a technical perspective by taking the stochastic nature of transitions and their prediction for the probability to be in various states into account. These probabilities are described by forward Kolmogorov equations. As we work with a discrete number of states, we obtain an ordinary differential equation system.7 The conclusion discusses various next steps that should be undertaken to understand economic consequences of COVID-19 better. We believe that our framework can form the basis for an understanding of the economic costs of the pandemic.8
This section describes what we know quantitatively about the spread of reported infections. We start with Hubei and its capital Wuhan in China. We afterwards look at South Korea and very briefly at Japan. We focus on the evolution of the number of individuals that were ever reported to be sick during the current epidemic. This number, by construction, can only rise. We chose Hubei and South Korea as the epidemics reportedly come to an end in these countries. Given the huge uncertainty about long-run infection rates and individual risk to display symptoms after an infection with CoV-2, we consider the long-run ratios of individuals reported sick to the overall population. This benchmark allows us to judge the credibility of our predictions for Germany. We are aware that we compare very different countries with very different cultural and political habits and medical systems. For reference, we also look at a cross section of infections for European countries. See the appendix for a description of data sources.9
Since the onset of the outbreak in the Hubei province in China, the number of confirmed cases has risen dramatically, peaking at 67,801 (WHO Situation Reports, 2020).10 Reporting began in January 2020 and we note that in mid-February, the WHO changed its classification methodology by reporting both clinically and lab confirmed cases rather than only lab confirmed cases. In terms of cumulative numbers, the total reported cases of infected individuals has risen continuously since January, since there has been continuous influx of new cases and very little communication about individuals transitioning back to being healthy.
When reporting began, the rise of new cases seemed to follow an exponential curve, with the number of new cases constantly increasing, however in early February, this trend stopped. Indeed, another trend then took over following a more S-shaped pattern, i. e. that of a sigmoidal function. The total number of reported cases over time is shown in Figure 1, which shows a clear explosive trend at the start of the outbreak before slowing down and approaching what appears to be an asymptote around 70,000.
To make this comparable to other countries, we take the population of around 59.17 million individuals in Hubei into account. This implies an infection rate of about 0.11 % or 1 person in 873 being infected in the long-run. While this is only one province, it does provide us with a reference point for what to expect in other regions of the world.
South Korea and Japan
Soon after China, South Korea, Japan, and many other countries all started seeing a rise in their number of confirmed cases. However, these countries have had very different experiences when it comes to infection outbreaks. Indeed, while South Korea has seen the number of confirmed cases rise to 9,241, Japan only has 1,307 confirmed cases (or 14 % that of South Korea). The question remains whether these countries are also experiencing a convergence to a stable number of (cumulative) confirmed cases. Figure 2 shows the cumulative number of confirmed cases in South Korea (left) and Japan (right).
The data from South Korea shows a reduction in the slope of the curve for total confirmed cases, indicating a significant drop in the number of new infections reported. Assuming the tendency continues, this would point toward South Korea progressively converging to a constant, similarly to the Hubei province in China. Japan on the other hand (as well as all other countries at this point) does not appear to slow down significantly. Relating South Korean infections to population size, we get a long-run infection rate of 1 in 5,337, with a peak number of confirmed cases of ca. 9,606.
In Europe, however, the situation continues to deteriorate, with new cases being reported by authorities on a daily basis numbering in the thousands (WHO Situation Reports, 2020). However, bearing in mind the lessons learned from the case of the Hubei province, and to a lesser extent from the case of South Korea, this current period of explosive growth should, in theory, be followed by a slow tapering leading to a plateauing of the total number of cases. We report in Table 1 the current infection rates in some European countries. The sample below represents 58 % of the total EU population, including Norway and Switzerland. This sample is by no means intended to be representative and is for illustrative purposes only by considering some of the most affected economies.
Current infection rates and risks in a sample of European countries.
|Country||Population||Confirmed cases||Infection rate (%)||Risk per 1 inhabitant|
|(1)||(2)||= (2)/(1)||= (1)/(2)|
|France (metro)||64,906,000||25,600||0.039 %||2,535|
|Sample total||308,143,212||214,724||0.070 %||1,435|
As we can see from Table 1, the degree of infection per country varies from 1 in 4,050 to 1 in 784, a fivefold ratio. Other countries fare better, the UK for example has a risk of 1 in 6,914, however we can clearly see that these figures are not yet as low as those in Hubei, with the exception of Italy and Switzerland, which are now below the 1 in 873 rate observed in the Chinese province, and Spain, which is approaching it fast. If this case is to be repeated, then things will likely worsen before they improve. However, with measures taken by governments, and progress being made on the medical front for an effective vaccine, there is still room for governments to curb these rates despite the rapid rise in cases.
3 The model
3.1 The structure
The model builds on a continuous time Markov chain with 4 states. We look at health of an individual i that can be in four states
3.2 Transition rates
Starting with the transition from being healthy to sick, each individual in state 1 has a certain average number of social contacts per day. We capture this by an exogenous arrival or contact rate a. Once a contact takes place, there is a certain probability that the contact is with an individual that can infect the healthy individual. If we assumed random contacts with healthy and sick individuals, this probability would be
In practice, individuals do not encounter sick individuals with this probability being equal to the share of sick individuals in society as sick individuals might stay at home or behave differently (not shaking hands or similar) than non-sick individuals. We do assume, however, that the probability
As is widely documented and reported (see e. g. Nishiura et al., 2020), there is also a flow of individuals that are infected but do not display any symptoms. We denote this flow by
3.3 Probabilities and means
The evolution of probabilities, shares and expected numbers
A standard law of large numbers tells us that individual probabilities also give shares in the population. Hence, when we solve this system, we can think of the time paths of
The probability to get sick per day
3.4 The number of individuals who become sick, ever were sick, and die
3.5 Model properties
Before we calibrate our model, we briefly discuss its theoretical predictions. This illustrates the plausibility of our assumptions and also the flexibility of the model. Our model consists of the ODE system (7) where we replace the probabilities
One can easily understand the plausible structure of our ODE system (7). The number
In the long-run, i. e. when the epidemic is over, individuals will be distributed across states 1, 3 and 4. Some individuals will never get infected. They therefore remain in state 1 all throughout the epidemic. This finding follows from the fact that the sickness rate
Our most important data source is the number of individuals that is reported to be sick. We obtain these outflows from state 1 to 2 from the Robert Koch Institute (RKI, 2020). These data fix the left-hand side of our time path for the number
It seems reasonable to assume that parameters are not constant throughout the entire epidemic. Most centrally, the contact rate a employed in the sickness rate (2) will change as a function of governmental regulations. The first major measures consisted in cancelling sports events (14 March) and closing schools (16 March). Other measures followed.18 Given a median incubation of 5.2 days (Linton et al., 2020, Lauer et al., 2020) and a certain delay between feeling symptoms, contacting a doctor and getting reported at RKI (say, 2–3 days), we employ
Data to compute the death rate from Corona are also taken from the RKI (2020). We finally employ various sources, to be discussed in what follows, to fix the share r of infected individuals that become sick and the long-run infection rate
4.2 Targets and parameters
A more open parameter for this epidemic (but for which there is a lot of information for other epidemics) is the long-run share of infected individuals, i. e. the limit
Parameters for the epidemic without public health measures.
We finally need to quantify r. A generally accepted benchmark says that around 80 % of infected individuals do not display any or only weak symptoms.20 The remaining share of 20 % falls sick. One crucial question for equation (4), but also for our long-run prediction from (12), is therefore the issue of reporting. If a large share of sick individuals show up at the general practitioner who does not test all individuals that display symptoms that might be caused by CoV-2, then the share r of individuals that are sick and reported will be much lower than these
Model for predictions
4.3 The goodness of fit of the calibration
We can judge the quality of our calibration in two ways. First, we can check the fit for observed number of individuals that were ever reported as sick,
The left part of Figure 4 shows the number of individuals that were ever reported as sick. The observations from RKI are depicted as circles. It shows that our parameter choices are sufficiently good to use this model for projections into the future.21 This impression is also confirmed from the right part of Figure 4. Obviously, fitting daily values is more demanding due to the greater variance in the data.
Figure 4 also shows where, in the case of no public health measures, Germany would be heading to. Under the assumption that the share of sick and reported individuals out of the infected individuals is
Note that this long run value does not only come out of the solution of our calibrated system (15). It can also be directly read from the long-run prediction in (12), which can be written as
5.1 The number of sick individuals and health care
The most important quantity coming out of our analysis is probably information about prevalence, i. e. the number
The number of sick individuals initially rises strongly. This is the consequence of infections. As recovery sets in only after 2 weeks, the initial period sees this strong increase. Once the number of new sick cases reduces (as the number of individuals in state 1 decreases) and recovery sets in, the number of sick individuals falls again. The peak will be reached in mid-May. We note that this is a prediction for the case where individual contacts, as captured by the parameter a in (2), remain unchanged over time. If the policy measures in place as of 14 March have an effect, we would expect a slowdown in the rise of
Figure 5 also provides the maximum number of infected individuals over the epidemic. This allows us to understand whether the number of extreme cases is always below the level that can be handled by the German health system. The peak of the number of sick individuals in mid-April is close to 220,000. According to the Deutsche Krankenhausgesellschaft (2020), there are 28,000 beds available in intensive care units (ICUs) in Germany. A fraction of these are currently available for the treatment of COVID-19 patients. Moreover, an undefined number of additional hospital facilities with ventilation systems might be available in due time through reorganization activities. By contrast, a large fraction of COVID-19 patients might be treatable in regular wards. While it is therefore difficult to pin down the precise number of beds available for COVID-19 patients, a peak of more than 1 million on a given day is definitely beyond any level that can be handled by the health care system. The prevention of such a scenario in the end has been the key issue of all measures currently taken by federal and state governments. We assess these measures in Section 6.
The one ‘advantage’ of a scenario without public health measures: the epidemic is over fast. As the infection rate is very high, the outflow from the state of being healthy is fast. Hence, a large share of individuals,
5.2 Individual risks
One of the concerns of individuals is that they might become infected. How large is this risk in a world without interventions?
As Figure 6 shows, the risk to fall sick for each individual from (8) is very low throughout the entire epidemic. At the peak, the probability to fall sick on a given day (blue curve) is around
We compare the daily risk of 1 in 10,000 or the weekly risk of 7 in 10,000 with the long-run risk of 7 in 100 by the end of the epidemic to be or have been sick (as discussed after Figure 4), it seems that at the individual level, the daily or even weekly risk of the epidemic is not really a major health risk.23 It is clear, however, that at the level of society, the epidemic is a major issue. This difference between the individual risk and aggregate outcomes is the result of a classic negative externality. Even individuals that take into account the overall risk of 7 in 100 to become sick might not be concerned. If the risk of infecting others was taken into account, individual behaviour would look differently. This is why governmental interventions have a clear justification from the perspective of market failure and public economics.
5.3 Robustness check
The long-run sickness rate r
Given uncertainty about the share r of individuals that become sick from an infection, we undertake robustness checks. Instead of our value of 0.1, we also solve our model for an r ten times lower and up to twice as large – as the left column of Table 3 shows. For each of these new values for r, we recalibrate the values for a and α to match the initial observations of sick individuals.
Varying the long-run sickness rate r.
|0.01||.685||.8289||.6952||182,004||23 April||15 July||19 May|
|0.025||.6707||.8397||.6113||440,135||2 May||4 Aug||24 May|
|0.05||.7505||.8513||.7921||775,478||8 May||25 Aug||25 June|
|0.1||.5751||.8662||.6459||14 May||7 Sep||17 June|
|0.2||.5481||.8847||.7511||19 May||27 Sep||16 June|
The model predictions are very reasonable from a qualitative perspective. The larger the individual risk r to get sick, the higher the number
We also find, as was to be expected, that a larger r implies a longer duration of the epidemic. If we define the end of the epidemic by the day
Why are these numbers important from a public health perspective? The data section shows that Hubei and South Korea seem to have managed to keep the long-run ratio
As no information is available at this point about the share of individuals that are already immune to CoV-2 in Germany, one might well hope that Germany is heading towards a Hubei long-run equilibrium. As data quality was often argued to be an issue, our long-run ratio
Infections via individuals without symptoms
We also inquire into the effect of η, i. e. into the share of healthy individuals that can infect other individuals. The value of η in Table 2 is 0.4 and we now vary it between .25 and .75. While there were qualitative changes (see appendix A.4), there are no quantitative changes that would be of importance for any public health questions.
6 The effect of policy measures
Given that an undamped spread of CoV-2 in society leads to high reported incidences
6.1 The experiments
6.2 The quantitative effects of policy measures
For this baseline analysis, we do not recalibrate the model as a in our scenarios changes after T, the day providing the last observation used for calibration. Parameter values are therefore given by the values in Table 2. The effect of various forms of shut downs are captured by a drop of the contact rate a by 50 % to
The results are shown in Figure 8. Our main variable for judging policy measures is the number
First, the policy is effective. Reducing contacts reduces the speed of infections and new cases of sickness – but also the transition from healthy in state 1 to healthy (with infection) in state 4. The case without shut down is illustrated by the red curve in Figure 8. It is identical to the curve in Figure 5. The shut down from (16) which reflects the planned closing of schools in Germany until in mid-April is drawn as the green curve. It reduces the rise of the number of sick individuals until mid-April. Afterwards, the number of sick individuals will rise more quickly again. The peak is reached in June and this peak is lower than the one without the shut down. In this respect the shut down is a good policy measure. When the shut down is extended (the black curve), the peak is further shifted to the right and also smaller.24
Quantitatively speaking, the shut down prolongs the epidemic in terms of its end as defined by
To be fair, we should stress at this point that the assumption that a shut down reduces the contact rate and thereby the infection rate by 50 % is open to empirical investigation. At this point, this is a model assumption for which empirical evidence is still lacking. Hartl et al. (2020) show that statistically convincing evidence will be available at the earliest beginning of April. It seems fair to say, however, that it can hardly be expected at this point that current measures reduce the infection rate by 50 %. Hence, the above evaluation of the shut down might even be too optimistic.25
Is a delayed shut down a good idea?
Interestingly, a delayed shut down (blue curve) is almost as good as an extended shut down and in some respect is even better: A delayed shut down reduces the peak in the number of sick individuals. Hospitals are therefore less crowded with a delayed shut down as opposed to an immediate shutdown. This implies, more generally speaking, that there is an optimal timing for a shut down.
Why is there an optimal point for a shut down? Imagine the shut down takes place early (green curve in Figure 8). Then the number of sick individuals does not increase that quickly. The downside is that, once the shut down is over, there are a lot of healthy individuals left that can become sick. The number of new incidences jumps up and the peak is reached quickly. When the shut down takes place later (the blue curve in Figure 8), the number of sick individuals is larger at the moment the shut down starts. Once the shut down is over, the number of healthy individuals that are left to become sick is not as large as in the case of an early shut down. As a consequence, the peak is less high.26
In a perfect world with complete knowledge about the number of sick individuals, the long run infection rate
The policy effects with lower
To return to the uncertainty about the value of the long-run share
Let us start with the long-run effects. As we know from (12), the long-run effects with
Concerning short-run effects, we see that in the case of no intervention (or interventions that do not have an effect), the peak comes earlier for
Most importantly, however, theses Figures 9 and 8 display a strong quantitative difference. If the long run infection rate in Germany is in the “data-quality adjusted Hubei range”, the peaks are at a much lower level. In the case without policy measures and in the case where the current shut down (16) is the only policy measure, the peaks of the simultaneously sick number of individuals is just above 200,000. This strongly contrasts to earlier values above 1 million. Another difference consists in the quantitative difference here between the extended shut down and the shut down. In the scenario with a lower long-run infection rate, an extended shut down implies that the peak of
When the long-run infection rate is in this Hubei-range, then the epidemic is also over more quickly than in the case of an infection rate of two thirds. In any case, the epidemic will last until June, in the case of extended shut downs (or other measures) it can even last until mid-July.
We have developed a model that allows us to study the spread of an infection in a society. We have solved this model and calibrated it to the COVID-19 epidemic in Germany. We employ the observed number of reported infections to match the initial increase of the number of sick individuals. In addition, we employ parameter values from the medical literature to quantify e. g. long-run infection rates or individual risks to become sick after an infection. Given uncertainty about the precision of these parameter values, we undertook robustness checks with respect to this long-run measure.
When we studied the effect of policy measures in Germany, we found that any intervention that reduces the contact rate of individuals reduces the strength of the epidemic. Both the peak of the number of simultaneously sick individuals as well as the individual sickness risk go down. This decrease is stronger the longer the policy measure lasts.
We also find, however, that there is an optimal point in time when an intervention, effective for a fixed length of time (say, 3 weeks), should start. When the intervention starts too early, there are “too many” healthy individuals left at the end of the intervention. The rise in the number of sick individuals would be accelerated. When the intervention starts later, the number of sick individuals is larger initially. Once the intervention is over, there are, as a consequence, not so many healthy individuals left and the peak is smaller. While implementing optimal schemes for real world societies probably requires too much information, this finding points towards implementing policy measures which are contingent on the current situation (number of sick individuals per capita) of a region or country.
In the long-run, for given parameters, the number of sick individuals is not affected by policy measures when the latter only reduce contact rates of individuals. All findings are subject to large uncertainty given little knowledge about long-run infection rates following a CoV-2 epidemic and individual sickness rates. It seems to be certain, however, that the epidemic will last at least until July, given the public health measures in place. Even in the case of a good scenario with extremely low long-run infection rates, the peak of the number of simultaneously sick individuals will lie above 200,000 individuals.
Many extensions of this framework are worth undertaking. First, optimal behaviour of individuals could be taken into account. The activity parameter a is like the outcome of decisions of individuals on how much to work and how much to enjoy social interactions. One can imagine a trade-off between reducing the risk of getting infected by lowering a and working fewer hours and thereby experiencing lower labour income. The same trade-off is present at the aggregate level to be tackled by a government. Such a trade-off might also include behavioural features like anxiety as in Caplin and Leahy (2001), potentially in a simplified way as presented in Wälde and Moors (2017). These extensions will help us to better understand the challenges posed by this pandemic.
A more detailed modelling of the long-run infection rate would also be useful. The path of social contacts over time should have an influence on the share of infected individuals in the long-run. A more detailed matching mechanism than the one employed here – borrowed in spirit from search and matching models – should be developed. This would also broaden the applicability of our framework to other epidemics and pandemics. The central trade-off faced by decisions makers about health costs vs. economic considerations should also be included in future work. Data on employment effects of COVID-19 should be forthcoming soon. A theoretical framework that allows to look at labour market effects should then prove useful to quantify this trade-off.
Finally, the calibration process employed here can be extended to full structural estimation. Further, the effects of the policy measures in place since 14 March can be estimated or calibrated. The calibration in this paper employs data up to the point where measures of 14 March should start having an effect. By the end of March, the intervention regime discussed above and the corresponding (reduced) contact rate could be quantified. This would provide a good idea of the effects of these policy measures.
A.1 Data sources
Data sources and calculations
The data used in this note is taken from two sources: (i) the World Health Organisation’s Situation reports on the progress of COVID-19, and (ii) the dataset put together by the nCoV-2019 Data Working Group (Dong et al. (2020)). In particular, wherever available the data from the nCoV-2019 Group is used instead of the data from the WHO, in an effort to remain as consistent as possible by using only one source at a time. Data from the nCoV-2019 Group is used as it provides a centralised and standardised repository of multiple official sources.
A.2 Intermediate steps for (15)
A.3 Goodness of fit
We provide a graphical illustration of how well our parameter choice via the minimization procedure in (14) fits the data.
A.4 Comparative statics for η
We assume that a share η of individuals in state 4 can infect individuals in state 1. This captures the fact that some infected individuals do not display symptoms but are nevertheless infectious. We vary the parameter η here to see how much the dynamics of prevalence
As this figure shows, the magnitude of η only has minor effects on prevalence
We are grateful to Matthias an der Heiden, Michael Bauer, Matthias Birkner, Christian Dormann, Oliver Emrich, Hoang Khieu, Dietmar Leisen, Kai Pastor, Olaf Posch, Ricardo Reis, Julien Riou, Perikles Simon, William Cannon Warren and members of the modelling initiative of the Deutsche Gesellschaft für Epidemiologie for comments and discussions. We are deeply indebted to Damir Stijepic for the initial numerical solutions and the initial calibration. We would also like to thank the editor and a referee for their support. Our biggest debt of gratitude is owed to Matthias Birkner who has been advising and teaching us on stochastic models for many years.
Achdou, Y., J. Han, J. Lasry, P. Lions, and B. Moll. 2020. “Income and Wealth Distribution in Macroeconomics: A Continuous-Time Approach.” mimeo Princeton University.
Akbarpour, M., and M. Jackson. 2018. “Diffusion in Networks and the Virtue of Burstiness.” PNAS 115(30): 1–9.
an der Heiden, M., and U. Buchholz. 2020. “Modellierung Von Beispielszenarien der SARS-CoV-2-Epidemie 2020 in Deutschland.” pp. 1–11. https://doi.org/10.25646/6571.2.
Anderson, R., B. Anderson, and R. May. 1992. Infectious Diseases of Humans: Dynamics and Control. Oxford university press.
Atkeson, A. G. 2020. “What Will Be the Economic Impact of COVID-19 in the US? Rough Estimates of Disease Scenarios.” NBER working paper 26867.
Balcan, D., B. Goncalves, H. Hu, J. Ramasco, V. Colizza, and A. Vespignani. 2010. “Modeling the Spatial Spread of Infectious Diseases: The Global Epidemic and Mobility Computational Model.” Journal of Computational Science 1(3).
Barro, R., J. Ursua, and J. Wenig. 2020. “The Coronavirus and the Great Influenza Epidemic Lessons from the ‘Spanish Flu’ for the Coronavirus’s Potential Effects on Mortality and Economic Activity.” CESifo Working Paper 8166. https://www.cesifo.org/en/publikationen/2020/working-paper/coronavirus-and-great-influenza-epidemic-lessons-spanish-flu.
Bayer, C., A. D. Rendall, and K. Wälde. 2019. “The Invariant Distribution of Wealth and Employment Status in a Small Open Economy with Precautionary Savings.” Journal of Mathematical Economics 85: 17–37.
Bayer, C., and K. Wälde. 2010. “Matching and Saving in Continuous Time: Proofs.” CESifo Working Paper 3026-A.
Caplin, A., and J. Leahy. 2001. “Psychological Expected Utility Theory And Anticipatory Feelings.” Quarterly Journal of Economics 116(1): 55–79.
Chinazzi, M., J. Davis, M. Ajelli, C. Gioannini, M. Litvinova, S. Merler, A. Pastore y Piontti, K. Mu, L. Rossi, K. Sun, C. Viboud, X. Xiong, H. Yu, H. Yu, E. Halloran, I. Jr. Longini, and A. Vespignani. 2020. “The Effect of Travel Restrictions on the Spread of the 2019 Novel Coronavirus (COVID-19) Outbreak.” Science 1–17. .
- Export Citation
Chinazzi, M., J. Davis, M. Ajelli, C. Gioannini, M. Litvinova, S. Merler, A. Pastore y Piontti, K. Mu, L. Rossi, K. Sun, C. Viboud, X. Xiong, H. Yu, H. Yu, E. Halloran, I. Jr. Longini, and A. Vespignani. 2020. “The Effect of Travel Restrictions on the Spread of the 2019 Novel Coronavirus (COVID-19) Outbreak.”)| false Science1–17. 10.1126/science.aba9757.
Deutsche Gesellschaft für Epidemiologie. 2020. “Stellungnahme der Deutschen Gesellschaft Für Epidemiologie (DGEpi) zur Verbreitung des Neuen Coronavirus (SARS-CoV-2).” Deutsche Gesellschaft Für Epidemiologie. pp. 1–4.
Diamond, P. A. 1982. “Aggregate Demand Management in Search Equilibrium.” Journal of Political Economy 90: 881–894.
Dong, E., H. Du, and L. Gardner. 2020. “An Interactive Web-based Dashboard to Track COVID-19 in Real-time.” The Lancet Infectious Diseases 1–2. .
Dorn, F., C. Fuest, M. Göttert, C. Krolage, S. Lautenbacher, S. Link, A. Peichl, M. Reif, S. Sauer, M. Stöckli, K. Wohlrabe, and T. Wollmershäuser. 2020. “Die Volkswirtschaftlichen Kosten des Corona-Shutdown Für Deutschland: Eine Szenarienrechnung.” ifo Schnelldienst 73(4).
Eichenbaum, M., S. Rebelo, and M. Trabandt. 2020. “The Macroeconomics of Epidemics.” https://sites.google.com/site/mathiastrabandt/home/downloads/EichenbaumRebeloTrabandt_EpidemicsMacro.pdf?attredirects=0.
Ferguson, N. M., D. Laydon, G. Nedjati-Gilani, N. Imai, K. Ainslie, M. Baguelin, S. Bhatia, A. Boonyasiri, Z. Cucunubá, G. Cuomo-Dannenburg, A. Dighe, I. Dorigatti, H. Fu, K. Gaythorpe, W. Green, A. Hamlet, W. Hinsley, L. C. Okell, S. van Elsland, H. Thompson, R. Verity, E. Volz, H. Wang, Y. Wang, P. G. Walker, C. Walters, P. Winskill, C. Whittaker, C. A. Donnelly, S. Riley, and A. C. Ghani. 2020. “Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID19 Mortality and Healthcare Demand.” Imperial College COVID-19 Response Team. pp. 1–20.
Gros, C., R. Valenti, K. Valenti, and D. Gros. 2020. “Strategies for Controlling the Medical and Socio-economic Costs of the Corona Pandemic.” https://arxiv.org/abs/2004.00493.
Guan, W., Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, d. Hui, B. Du, L. Li, G. Zeng, K.-Y. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang, S. Li, J.-l. Wang, Z. Liang, Y. Peng, L. Wei, Y.-h. Hu, P. Peng, J.-m. Wang, J. Liu, Z. Chen, Z. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, and N. Zhong. 2020. “Clinical Characteristics of Coronavirus Disease 2019 in China.” The New England Journal of Medicine 1–12. .
- Export Citation
Guan, W., Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, L. Liu, H. Shan, C. Lei, d. Hui, B. Du, L. Li, G. Zeng, K.-Y. Yuen, R. Chen, C. Tang, T. Wang, P. Chen, J. Xiang, S. Li, J.-l. Wang, Z. Liang, Y. Peng, L. Wei, Y.-h. Hu, P. Peng, J.-m. Wang, J. Liu, Z. Chen, Z. Li, Z. Zheng, S. Qiu, J. Luo, C. Ye, S. Zhu, and N. Zhong. 2020. “Clinical Characteristics of Coronavirus Disease 2019 in China.”)| false The New England Journal of Medicine1–12. 10.1101/2020.02.06.20020974.
Hartl, T., K. Wälde, and E. Weber. 2020. “Bundesliga, Schulen, Kinos – Wann Wissen Wir, Ob die Maßnahmen Gegen Corona Etwas Gebracht Haben?” https://www.macro.economics.uni-mainz.de/corona-blog/. Einschätzung vom 23. März.
Hellewell, J., S. Abbott, A. Gimma, N. Bosse, C. Jarvis, T. Russell, J. Munday, A. Kucharski, W. Edmunds, S. Funk, and R. Eggo. 2020. “Feasibility of Controlling COVID-19 Outbreaks by Isolation of Cases and Contacts.” The Lancet Global Health 8:e488–e496.
Hethcote, H. 2000. “The Mathematics of Infectious Diseases.” SIAM Review 42(4): 559–653.
Kaplan, G., B. Moll, and G. L. Violante. 2018. “Monetary Policy According to HANK.” American Economic Review 108:697–743.
Khieu, H., and K. Wälde. 2020. “Capital Income Risk and the Dynamics of the Wealth Distribution.” mimeo Johannes Gutenberg University Mainz.
Deutsche Krankenhausgesellschaft. 2020. “Coronavirus: Fakten und Infos.” https://www.dkgev.de/dkg/coronavirus-fakten-und-infos/.
Lachmann, A. 2020. “Correcting Under-reported COVID-19 Case Numbers.” pp. 1–5. medRxiv preprint. https://doi.org/10.1101/2020.03.14.20036178.
Lauer, S., K. Grantz, Q. Bi, F. Jones, Q. Zheng, H. Meredith, A. Azman, N. Reich, and J. Lessler. 2020. “The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.” Annals of Internal Medicine 1–7. .
- Export Citation
Lauer, S., K. Grantz, Q. Bi, F. Jones, Q. Zheng, H. Meredith, A. Azman, N. Reich, and J. Lessler. 2020. “The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application.”)| false Annals of Internal Medicine1–7. 10.7326/M20-0504.
Linton, N., T. Kobayashi, Y. Yang, K. Hayashi, A. R. Akhmetzhanov, S.-m. Jung, B. Yuan, R. Kinoshita, and H. Nishiura. 2020. “Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data.” Journal of Clinical Medicine 9(2) (538): 1–9.
Mortensen, D. T. 1982. “Property Rights and Efficiency in Mating, Racing, and Related Games.” American Economic Review 72: 968–979.
Nishiura, H., T. Kobayashi, A. Suzuki, S.-M. Jung, K. Hayashi, R. Kinoshita, Y. Yang, B. Yuan, A. Akhmetzhanov, and N. Linton. 2020. “Estimation of the Asymptomatic Ratio of Novel Coronavirus Infections (COVID-19).” International Journal of Infectious Diseases 1–7. Journal Pre-proof. .
- Export Citation
Nishiura, H., T. Kobayashi, A. Suzuki, S.-M. Jung, K. Hayashi, R. Kinoshita, Y. Yang, B. Yuan, A. Akhmetzhanov, and N. Linton. 2020. “Estimation of the Asymptomatic Ratio of Novel Coronavirus Infections (COVID-19).”)| false International Journal of Infectious Diseases1–7. Journal Pre-proof. 10.1016/j.ijid.2020.03.020.
Pissarides, C. A. 1985. “Short-run Equilibrium Dynamics of Unemployment Vacancies, and Real Wages.” American Economic Review 75:676–690.
Riou, J., and C. Althaus. 2020. “Pattern of Early Human-to-human Transmission of Wuhan 2019 Novel Coronavirus. (2019-nCoV), December 2019, to January 2020.” Eurosurveillance 25(4).
Robert Koch Institut (RKI). 2020. “COVID-19: Fallzahlen in Deutschland und Weltweit.” https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Fallzahlen.html.
Ross, S. M. 1993. Introduction to Probability Models, 5th ed. San Diego: Academic Press.
Simon, P. 2020. “Deutschland, Welches Horrorszenario Willst Du? Man Sollte die Katastrophe Vom Ende Her Berechnen!” pp. 1–3. mimeo University Mainz.
Statistisches Bundesamt. 2020. “Bevölkerungsstand.” https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Bevoelkerungsstand.
Toda, A. A. 2020. “Susceptible-infected-recovered (SIR) Dynamics of Covid-19 and Economic Impact.” Covid Economics, Vetted and Real-time Papers, 1. 43–63. CEPR press.
Wälde, K., and A. Moors. 2017. “Current Emotion Research in Economics.” Emotion Review 9: 271–278.
Wilder-Smith, A., C. Chiew, and V. Lee. 2020. “Can We Contain the COVID-19 Outbreak with the Same Measures as for SARS?” Lancet Infect Dis.
World Health Organization. 2020. “Coronavirus Disease 2019 (COVID-19): Situation Report – 46.” https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200306-sitrep-46-covid-19.pdf?sfvrsn=96b04adf_4.
Wu, Z., and J. M. McGoogan. 2020. “Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72?314 Cases from the Chinese Center for Disease Control and Prevention.” JAMA. https://doi.org/10.1001/jama.2020.2648.
Ying, Y., P. Mo, Y. Xiao, O. Zhao, Y. Zhang, and F. Wang. 2020. “Post-discharge Surveillance and Positive Virus Detection in Two Medical Staff Recovered from Coronavirus Disease 2019 (COVID-19), China, January to February 2020.” Euro Surveill. 25(10): 1–4. .
- Export Citation
Ying, Y., P. Mo, Y. Xiao, O. Zhao, Y. Zhang, and F. Wang. 2020. “Post-discharge Surveillance and Positive Virus Detection in Two Medical Staff Recovered from Coronavirus Disease 2019 (COVID-19), China, January to February 2020.”)| false Euro Surveill.25(10): 1–4. 10.2807/1560-7917.
We emphasize that all projections are subject to uncertainty and permanent monitoring of observed incidences are taken into account to update the projection. The most recent projections are available at https://www.macro.economics.uni-mainz.de/corona-blog/
There are also various internet pages that offer projections for parameter models that can be chosen by the user. Examples include https://gabgoh.github.io/COVID/index.html, https://neherlab.org/covid19/ or http://covidsim.eu/. These pages usually do not show the details of the model and a comparison to our approach is therefore difficult.
Eichenbaum et al. (2020) study the effects of the CoV-2 epidemic on economic decisions of households. They emphasize the household decisions to reduce labour supply exacerbate the recessionary effects of the epidemic. They apply their model to the US. Barro et al. (2020) employ mortalities and economic consequences of the “Spanish Flu” to provide estimates of the world wide consequences of COVID-19. They do not offer a detailed projection for Germany. The costs for Germany are estimated by Dorn et al. (2020). Atkeson (2020) provides estimates of economic consequences of COVID-19 for the US.
An application of the SIR model, the benchmark model of epidemiology, to the COVID-19 pandemic including economic implications is undertaken by Toda (2020).
When working with continuous states like e. g. wealth or labour income, partial differential equations result. See e. g. Bayer and Wälde (2010), Achdou et al. (2020), Kaplan et al. (2018) or Khieu and Wälde (2020).
A framework that analyses the trade-off between public health considerations and economic costs was developed by Gros et al. (2020). Given the current uncertainty about the length of the epidemic, all estimates of economic costs for Germany are also subject to large variability. Observations about e. g. employment effects of COVID-19 are still lacking. In work in progress we develop an extended framework that allows to incorporate both labour market and health effects.
Note that all figures below are as of 21 March 2020 and come from the Johns Hopkins University dataset from Dong et al. (2020).
There are attempts to correct supposedly under-reported numbers from China by employing South Korea as a benchmark country (Lachmann, 2020).
In our quantitative solution below, the initial state follows from the number of reported sick individuals on 24 February 2020.
Individuals that have died no longer play a role in social interactions. Hence,
A parallel can be drawn between ϕ and a matching function, and
We employ “around” as some individuals will have ended up in state 3 whose number does not enter the expression in (1).
One could plausibly argue and find support in micro studies that the death and recovery rate also depend on the number of healthy individuals (that are required to take care of sick individuals). These considerations are not crucial for our macro analysis and are therefore neglected.
Some individuals sick with COVID-19 are hospitalized. An extension of the model could include a hospital state with inflows from state 2. Outflows from the hospital state are then into state 3 and state 4. Flows from state 2 to state 4 should be kept in such an extension as not all COVID-19 patients are hospitalized.
Let us denote the expected number of individuals in state s at t by
See https://www.macro.economics.uni-mainz.de/corona-blog/ for more details.
One might conjecture to employ so-called reproduction numbers to get an idea about
Figure 4 intuitively shows that in the medium-run, the long-run sickness share
This might explain behaviour of some individuals who seem to ignore governmental pleas to reduce social interactions.
If we had a sequence of shut downs with breaks in between, it would qualitatively look like a combination of the green and the blue curve. The green curve represents a shut down that ends by the end of April where the green curve starts rising quickly again. Then when a new shut down takes place as of mid-May, the number of sick individuals would follow the blue curve. When the “blue shut down” ends by the end of May, the number of sick individuals starts rising again as shown by the blue curve.
All of our scenarios could look much more optimistic if we had a vaccine. To the best of our knowledge, this will not be available within the next 6 months.
We understand that from a policy perspective it is simpler to “sell a measure” that is the same for everybody than measures that differ across individuals. Yet, treating unequals as equals has rarely been a convincing idea.